logo de apored
Integrantes
spacio
PresentaciónIntegrantesInvestigacionDivulgacionEventosEnlaces
Ir al mapa web  
Biogénesis y Función de la Mitocondria y su Repercusión en Patología
IDIBAPS

 

Grupo coordinado por Patricia Pérez-Galán

IDIBAPS
Rosello 149-153, 2nd floor. Office 2.1
08036 Barcelona

Tel: +34932275400 ext 4525
Fax:+34 933129407
Correo electrónico: pperez@clinic.ub.es

  1. Invited speaker to school of hematology sessions. HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA.
  2. Evaluator of the Croatian Unity through Knowledge Fund. UKF's Researc Cooperability Program: Crossing Borders Grant
  3. Doctoral thesis tribunal (Patricia Balsas Clavería) Universidad de Zaragoza 19/05/2011
  4. Doctoral thesis tribunal (Anna Mozos Rocafort). Universitat de Barcelona 05/03/2012
  5. Doctoral thesis tribunal (Patricia Galán Malo). Universidad de Zaragoza. 05/05/2010
  6. Peer reviewer of the scientific journals: Clinical Cancer Reserach, Blood, Leukemia, Haematologica, Leukemia Lymphoma, Future Medicine
  7. Prize Ernst Schering 2006 in Hematology: Best Spanish publication in lymphoproliferative disorders: Pérez-Galán P et al.Blood 2006 Jan 1;107(1):257-64) Tecnhology transfer activity: Translation into clinical trials of the therapeutic combination Bortezomib and GX15-070 (Pérez-Galán et al. Blood 2007;109(10):4441-9): ClinicalTrials.gov Identifier NCT00407303; ClinicalTrials.gov Identifier NCT00538187; ClinicalTrials.gov Identifier NCT00719901

 



Miembros del grupo

  • Alba Matas Céspedes, PhD student
  • Anna Vidal Crespo, PhD student
  • Martina Guerrero, PhD student
  • Clara Recasens, PhD student
  • Vanina Rodriguez, Lab and Animal technician

ir a principio de  página


Líneas de Investigación

  • Characterization of molecular pathways activated by microenvironment in follicular and mantle cell lymphoma, as a discovery tool of new therapeutic targets and resistance to treatments (financed by projects 2, 3, 4 and 6)
  • Simultaneous targeting of chemokine and cannabinoid receptors by bi-functional compounds in in vitro and in vivo models of non-Hodgkin lymphoma (NHL)(financed by projects 1 and 3)
  • New antibody therapy in NHL: Study of the potential therapeutic effect of the novel anti-CD38 antibody  in  in vitro and in vivo models of non-Hodgkin lymphoma (NHL )(financed by projects 7,8 and 9)

ir a principio de  página


Publicaciones

  • Matas-Céspedes; V. Rodríguez; S.G. Kalko; A. Vidal-Crespo; Rosich, L.; Caserras, T.; P. Balsas; Villamor, N.; Gine, E.; E. Campo; G. Roué; López-Guillermo, A.; D. Colomer; P. Pérez-Galán. Disruption of follicular dendritic cells - follicular lymphoma crosstalk by the pan-PI3K inhibitor BKM120 (buparlisib). Clinical Cancer Research. 2014 May 5. [Epub ahead of print].  Impact Factor: 7.837. Q1 and D1
  • Moros A, Rodríguez V, Saborit-Villarroya I, Montraveta A, Balsas P, Sandy P, Martínez A, Wiestner A, Normant E, Campo E, Pérez-Galán P, Colomer D, Roué G. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia. 2014 Mar 18. [Epub ahead of print]. Impact factor 10.164. Q1 and D1
  • López-Guerra M, Xargay-Torrent S, Rosich L, Montraveta A, Roldán J, Matas-Céspedes A, Villamor N, Aymerich M, López-Otín C, Pérez-Galán P, Roué G, Campo E, Colomer D. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.
    Leukemia. 2014 Apr 30. [Epub ahead of print]. Impact factor 10.164. Q1 and D1
  • Arnau Montraveta, Sílvia Xargay-Torrent, Mónica López-Guerra, Laia Rosich, Patricia Pérez-Galán, Itziar Salaverria, Silvia Beà, Susana G. Kalko, Mercè de Frias, Clara Campàs, Gaël Roué, Dolors Colomer. Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma. Oncotarget. 2014 Mar. 5(3):726-39. Impact factor 6.636. Q1
  • Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M, Liu D, Keyvanfar K, Chapman CM, Chen J, Buggy JJ, Aue G, Tisdale JF, Pérez-Galán P*, Wiestner A*. *co-seniorship. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia 2013 Dec. 27  (12) : 2311-2321. Impact factor 10.164. Q1 and D1
  • Rosich L, Saborit-Villarroya I, López-Guerra M, Xargay-Torrent S, Montraveta A, Aymerich M, Villamor N, Campo E, Pérez-Galán P, Roué G, Colomer D. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. Haematologica 2013 Nov. 98(11):1739-47. Impact factor: 5.935. Q1
  • Vegliante MC, Palomero J, Pérez-Galán P, Roué G, Castellano G, Navarro A, Clot G, Moros A, Suárez- Cisneros H, Beà S, Hernández L, Enjuanes A, Jares P, Villamor N, Colomer D, Martín-Subero JI, Campo E, Amador V. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 2013 Mar 21. 121 (12):2175-85. Impact factor 9.060. Q1 and D1
  • Xolalpa W*, Perez-Galan P*, Rodríguez MS, Roue G. *co-first authors Targeting the Ubiquitin Proteasome System: beyond proteasome inhibition. Curr Pharm 2012 Nov 23.  19(22):4053-93. Impact factor: 4.774
  • Xargay-Torrent S, Lopez-Guerra M, Montraveta A, Saborit-Villarroya I, Rosich L, Navarro A, Pérez-Galán P, Roue G, Campo E, Colomer D. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma. Clin Cancer Res 2013 Feb1.19 (3): 586-597.  Impact Factor: 7.837. Q1 and D1
  • López-Guerra M, Xargay-Torrent S, Pérez-Galán P, Saborit-Villarroya I, Rosich L, Villamor N, Aymerich M, Roué G, Campo E, Montserrat E, Colomer D.Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. Leukemia 2012 Jun. 26(6):1429-32. Impact factor 10.164. Q1 and D1
  • Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, Gibellini F, Arthur D, Pérez-Galán P*, Wiestner A*.  *co-seniorshipON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.
    Clin Cancer Res 2012 Apr 1. 18(7):1979-91. Impact Factor: 7.837. Q1 and D1
  • Dreyling, M ; Kluin-Nelemans, HC, Bea, S, Hartmann, E , Salaverria, I,  Hutter, G,  Perez-Galan, P, Roue, G, Pott, C, Le Gouill, S, Cortelazzo, S Rule, S, Hess, G, Zaja, F, Vitolo, U, Szymczyk, M, Walewski, J .Ribrag, V, Unterhalt, Hermine, O., Hoster, E. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. LEUKEMIA & LYMPHOMA Dec 2011. 52 (12) 2226-2236. Impact Factor: 2.301
  • Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, Wiestner A.  Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res. 2011 Aug. 17(15):510. Impact Factor: 7.837. Q1 and D1
  • Roué G, Pérez-Galán P, Mozos A, López-Guerra M,  Xargay-Torrent S, Rosich L, Saborit-Villarroya I, Normant E, Campo E and  Colomer D. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood  2011 Jan. 117(4): 1270-79. Impact factor 9.060. Q1 and D1
  • Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood  2011 Jan. 117(1):26-38. Impact factor 9.060. Q1 and D1
  • Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson M, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A. The lymph node microenvironment promotes B-cell receptor signaling, NF-{kappa}B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood  2011 Jan 117(2) 563-74. Impact factor 9.060. Q1 and D1
  • Pérez-Galán P, Mora-Jensen H, Weniger MA, Shaffer AL 3rd, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy KM, Wilson WH, Staudt LM, Wiestner A. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 2011 Jan 117(2) 542-52. Impact factor 9.060. Q1 and D1
  • López-Royuela N, Pérez-Galán P, Galán-Malo P, Yuste VJ, Anel A, Susín SA, Naval J, Marzo I. Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells. Biochem Pharmacol. 2010  Jun .79(12):1746-58.Impact factor 4.576. Q1
  • P. Pérez-Galán; G. Roué; M. López-Guerra; M. Nguyen; N. Villamor; E. Montserrat; G.C. Shore; E. Campo; D. Colomer. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia. 22 - 9, pp. 1712 - 1720. 2008. ISSN 0887-6924. Leukemia 2012 Jun. 26(6):1429-32. Impact factor 10.164. Q1 and D1
  • P. Pérez-Galán; G. Roué; N. Villamor; E. Campo; D. Colomer. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood. 109 - 10, pp. 4441 - 4449. 2007. Impact factor 9.060. Q1 and D1
  • P. Pérez-Galán; G. Roue; N. Villamor; E. Montserrat; E. Campo; D. Colomer. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 107 - 1, pp. 257 - 264. 2006. Impact factor 9.060. Q1 and D1
  • P. Pérez-Galán; I. Marzo; P. Giraldo; D. Rubio-Félix; P. Lasierra; L. Larrad; A. Anel; J. Naval. Role of caspases and apoptosis-inducing factor (AIF) in cladribine-induced apoptosis of B cell chronic lymphocytic leukemia. Leukemia. 16 - 10, pp. 2106 - 2114. 2002. Impact factor 10.164. Q1 and D1

ir a principio de  página


Proyectos de Investigación y Contratos

  • Name of the project: Targeting proliferation and tumor-microenvironment interactions using bifunctional compounds against cannabinoid and chemokine receptors.
    Duration:
    3 years (2014-2017)
    Funding institution or bodies: Fundació La marato TV3
    Role: PI and coordinator of the project
  • Name of the project: Microenvironment Interactions in the pathogenesis of lymphoid neoplasms and chronic inflammatory disorders. Identification of biomarkers and design of new therapeutic strategies
    Duration:
    3 years (2014-2017)
    Funding institution or bodies: Instituto de Salud Carlos III (Transversal projects)
    Role: PI
  • Name of the project: Red cooperativa en Cáncer (RTICC)
    Duration: 3 years (2013-2015)
    Funding institution or bodies: Instituto de Salud Carlos III
    Role: collaborator
  • Name of the project: Hemafarma: Pharmaceutical development of based on apoptosis for hematological cancers classified as rare diseases
    Duration: 2 years (2013-2014)
    Funding institution or bodies: MINECO
    Role: collaborator
  • Name of the project: Targeting the interaction between the tumor cell and its microenvironment: a new therapeutic approach for the treatment of Follicular Lymphoma
    Duration: 3 years (2012-2014)
    Funding institution or bodies: MINECO
    Role: PI
  • Name of the project: Characterization of the mechanisms of microenvironment-derived resistance to GS-1101/ Idelalisib in follicular lymphoma
    Duration: 1 year (2014-2015)
    Funding institution or bodies: Gilead
    Role: PI
  • Name of the project: Combinatorial effect of HuMax-CD38 (Daratumumab) and ibrutinib in in vivo models of CLL and MCL
    Duration: 1 year (2014-2015)
    Funding institution or bodies: Janssen Pharmaceuticals
    Role: PI
  • Name of the project: HuMax-CD38 (Daratumumab) activity in in vivo models of MCL and FL: Analysis of possible combinatorial regimens
    Duration: 1 year (2014-2015)
    Funding institution or bodies: Janssen Pharmaceuticals
    Role: PI
  • Name of the project: HuMax-CD38 (Daratumumab), a novel agent for the treatment of Chronic Lymphocytic Leukemia and B-cell Non–Hodgkin Lymphoma: cytotoxic activity, mechanism of action, and ability to inhibit tumor-microenvironment interactions
    Duration: 3 year (2011-2014)
    Funding institution or bodies: Genmab
    Role: PI

 

ir a principio de  página


Tesis Doctorales

  • Doctorate student: Clara Recasens Zorzo
    Project title: New therapeutic approaches in follicular and diffuse large B cell lymphoma
    Type of project: Doctoral thesis
    University issuing the qualification: Universitat de Barcelona
    Role of the researcher: Director
    Status: Ongoing. Planned for 03/2017
  • Doctorate student: Martina Guerrero
    Project title: Targeting proliferation and tumor-microenvironment interactions using bifunctional compounds
    against cannabinoid and chemokine receptors
    Type of project: Doctoral thesis
    University issuing the qualification: Universitat de Barcelona
    Role of the researcher: Director
    Status: Ongoing. Planned for 06/2017
  • Doctorate student: Alba Matas Céspedes
    Project title: New therapeutic approaches in B-cell neoplasia
    Type of project: Doctoral thesis
    University issuing the qualification: Universitat de Barcelona
    Role of the researcher: Director
    Status: Ongoing. Planned for 11/2016
  • Doctorate student: Anna Vidal Crespo
    Project title: Interference with microenvironment-tumor cell crosstalk: a new therapeutic approaches in lymphoid neoplasia
    Type of project: Doctoral thesis
    University issuing the qualification: Universitat de Barcelona
    Role of the researcher: Director
    Status: Ongoing. Planned for 03/2017
  • Doctorate student: Alba Matas Céspedes
    Project title: New therapeutic approaches in in follicular lymphoma
    Type of project: Minor thesis
    University issuing the qualification: Universitat de Barcelona
    Role of the researcher: Director
    Date of reading :15/07/2011

ir a principio de  página


Patentes

  1. Raimon Puig de la Bellacasa Cazorla, Gaël Roué, Patricia Pérez Galán, Jordi Teixidó, Dolors Colomer Pujol, José Ignacio Borrell
    TITULO:  4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF
    Número de patente: EP13382225.4  (Patente Europea)
    Fecha de solicitud: 14/06/2013
    Entidad titular: Institut d'Investigacions Biomèdiques August Pi i Sunyer

 

ir a principio de  página

   
   
Socios protectores